Last updated: February 13, 2026
Overview
NDC 75826-0165 is identified as Oxycodone Hydrochloride Extended-Release (ER) capsules, marketed under the brand name OxyContin. It is approved for moderate to severe pain management and controlled under opioid regulations. The patent landscape, manufacturing trends, and market demand influence its pricing and projections.
Market Size and Demand
Global and U.S. Market
- The global opioid analgesics market was valued at approximately $10 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4.5% through 2030 (source: MarketsandMarkets).
- The U.S. accounts for nearly 80% of the opioid market, with sales reaching $8 billion annually prior to recent regulatory adjustments.
Prescription Trends
- U.S. prescribed opioid dosage increased post-2010, peaking around 2016, then declining due to regulatory crackdowns.
- In 2022, approximately 31 million prescriptions for extended-release opioids were written in the U.S. (source: IQVIA).
Market Drivers
- Chronic pain prevalence affecting 20% of adults in the U.S.
- Limited effective alternatives for long-term pain management.
- Recent approval of abuse-deterrent formulations aimed at reducing misuse.
Market Challenges
- Stringent regulatory controls and abuse concerns have limited new formulations' market entry.
- Increasing litigation and reformulation pushed existing manufacturers to reformulate or restrict supplies.
Regulatory and Patent Context
Patent Status
- The original patent for OxyContin expired in 2027.
- Extended-release formulations typically enjoy patent protections of 8-12 years, with exclusivity periods influencing pricing.
- Market remodulation involves formulations with abuse-deterrent properties granted exclusivity until 2030.
Federal and State Regulations
- The DEA schedules such drugs as Schedule II controlled substances.
- Prescriber restrictions have tightened, impacting overall prescription volumes.
- State-level prescription drug monitoring programs (PDMPs) have decreased unauthorized prescribing.
Price Trends and Projections
Historical Pricing
| Year |
Average Wholesale Price (AWP) per 30mg capsule |
Notes |
| 2018 |
$3.50 |
Pre-AB (abuse-deterrent) formulations |
| 2020 |
$4.20 |
Introduction of reformulated products |
| 2022 |
$4.80 |
Market stabilization |
Factors Influencing Price
- Patent protection and exclusivity prolongs high pricing.
- The adoption rate of abuse-deterrent formulations causes shifts in market share.
- Regulatory pressures reduce prescribing volume, suppressing demand and pacing price decreases.
Price Projection (Next 5 Years)
| Year |
Projected AWP |
Change from Previous Year |
Assumptions |
| 2023 |
$4.90 |
+2.1% |
Slight increase due to inflation and demand stabilization |
| 2024 |
$4.85 |
-0.5% |
Market saturation and prescriber caution |
| 2025 |
$4.75 |
-2.0% |
Continued regulatory impact and generics entry |
| 2026 |
$4.50 |
-5.3% |
Significant generics penetration, price decline |
| 2027 |
$4.20 |
-6.7% |
Patent expiry, increased competition |
Note: These projections rely on historical trends, patent expiry, regulatory climates, and generic market entries.
Generic Competition Impact
- The entry of generic alternatives post-2027 is expected to reduce prices by approximately 40-60%, aligning with generics' typical market share and pricing dynamics.
- Historically, generic versions sell at 50-70% of branded prices, depending on market acceptance and distribution channels.
Market Opportunities and Risks
Opportunities
- Increasing demand for pain management despite regulatory hurdles.
- New abuse-deterrent formulations extending market exclusivity periods.
- Potential non-opioid alternatives gaining regulatory approval for long-term pain treatments.
Risks
- Regulatory crackdown lowering prescription volumes.
- Legislation restricting opioid prescribing and increasing restrictions.
- Growing societal and legal pressures to reduce opioid consumption.
Key Takeaways
- The current market for NDC 75826-0165 (OxyContin ER) remains significant mainly in pain management, with U.S. prescriptions accounting for the majority.
- Patent protections and abuse-deterrent formulations sustain higher prices until approximately 2027–2028.
- Post-patent expiry, prices are projected to decline sharply owing to the influx of generics.
- Regulatory environment and societal shifts toward reducing opioid use pose ongoing risks and suppress market growth.
- Market valuations and price projections should incorporate adjustments for legal, regulatory, and competitive changes over the next five years.
FAQs
1. When will generic versions of NDC 75826-0165 likely enter the market?
Post-2027, following patent expiry, with generics pricing 50-70% lower than branded prices.
2. How do regulatory changes influence price projections?
They can decrease prescription volumes, leading to downward pressure on prices. Stricter prescribing rules may also accelerate generic adoption.
3. What is the impact of abuse-deterrent formulations?
They extend exclusivity periods, sustaining higher prices but have not prevented a decline in overall demand due to regulatory restrictions.
4. Are there any legal risks affecting the market for this drug?
Yes, ongoing litigation and legislative measures aim to curb opioid prescriptions, impacting demand and pricing.
5. How do market trends compare internationally?
Non-U.S. markets have varying regulations and consumption levels, generally with lower usage, affecting global sales and prices.
Citations:
[1] MarketsandMarkets, “Opioid Analgesics Market," 2023.
[2] IQVIA, “2018-2022 Prescription Data," 2022.
[3] U.S. FDA, “Drug Approval and Patent Data,” 2023.
[4] DEA, “Controlled Substances Scheduling,” 2023.
